Actively Recruiting
Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans
Led by First Affiliated Hospital, Sun Yat-Sen University · Updated on 2025-08-08
400
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease. It is expected to include about 400 patients diagnosed with lower extremity arterial occlusive disease in our center from July 2024 to July 2026. All enrolled patients will be followed for three years. All patients diagnosed with arteriosclerosis obliterans (ASO) and all treatment techniques were included in this study. The primary outcomes include the Efficacy and Safety End Points of each techniques.
CONDITIONS
Official Title
Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, gender is not limited.
- Patients diagnosed with arteriosclerosis obliterans.
- Rutherford stages 2-6.
- When there are multiple stenosis lesions, the treatment of the most severe lesion is included.
- Patients with at least one arterial occlusion ( iliac, femoral, popliteal, anterior tibial, posterior tibial, and/or peroneal artery) of the lower extremity were included.
You will not qualify if you...
- Malignant tumor
- Alzheimer's disease
- Blood disease or bleeding tendency
- Heart Failure Grade III ~ IV
- Pregnancy or lactation
- An above-knee-below-knee amputation has been performed
- Unable to accept therapeutic function tests
- Life expectancy is less than six months
- Combined with other diseases affecting walking
- Cardiovascular and cerebrovascular events occurred within 3 months, including non-fatal myocardial infarction, unstable angina, stable angina, non-fatal ischemic stroke and hemorrhagic stroke
- Patients with significant abnormal liver and renal function that the investigators judged to be clinically significant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510030
Actively Recruiting
Research Team
H
Haoliang Wu
CONTACT
Z
Zilun Li
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here